Since Gristle wanted to change the subject of another thread to what states do, I figured this would be of interest.
Let's see people defend this one:
T
he New York State Department of Health (NYSDOH) published a new memo outlining two COVID-19 oral antiviral therapies that have received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) are in short supply.
NYSDOH said the newly authorized oral antiviral treatments, including Paxlovid (Pfizer) and molnupiravir (Merck), are in "limited supply will require providers to prioritize treatment for patients at highest risk for severe COVID-19 until more product becomes available."
The department prioritizes those who are severely immunocompromised or have at least one risk factor for severe illness can receive oral antiviral treatments. Besides some risk factors that include cancer, diabetes, dementia, and or other debilitating diseases, the NYSDOH list being non-white "should be considered a risk factor, as long-standing systemic health and social inequities have contributed to an increased risk of severe illness and death from Covid-19."
https://www.zerohedge.com/markets/no...rce-covid-pill
Non-White New Yorkers To Receive Priority For Scarce Life-Saving COVID Pill
